Verrica Posts Profit in Fiscal Q2

Verrica Pharmaceuticals (NASDAQ:VRCA), a specialty dermatology company focused on skin disease treatments, released its earnings for the second quarter of fiscal 2025 on August 12, 2025. The quarter’s headline news was a large upside surprise in both profitability and revenue, with non-GAAP EPS of $0.25 and GAAP revenue of $12.7 million, both significantly exceeding analyst estimates. The company reported Non-GAAP earnings per share of $0.25, which was well above analyst estimates of a $0.90 loss (non-GAAP), and delivered GAAP revenue of $12.7 million -- Revenue (GAAP) of $12.7 million exceeded analyst estimates of $4.3 million by 197.7%. These results reflect strong commercial progress with YCANTH® (VP-102) and the impact of a major milestone payment from a strategic collaboration. The quarter also saw improved efficiency through ongoing expense control, leading to a substantially better bottom line (GAAP net income of $0.2 million vs. GAAP net loss of $17.2 million for Q2 2024). Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Verrica Pharmaceuticals specializes in developing and commercializing treatments for common dermatological conditions. Its lead product, YCANTH (VP-102), is approved for molluscum contagiosum, a skin disease affecting millions. The company's business model blends in-house development with external collaborations and licensing deals to expand its reach and accelerate pipeline growth.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool